RxDoctor Payments Data

Brian Hess, MD

Internal Medicine · Billings, MTNPI 1124514609

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $5,460 of the $7,841 with a category attached, or 69.6%. E.r. Squibb & Sons, L.L.C. accounts for 94.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $7,388, more than ten times the $229 reported in 2019. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,841in general payments, 2019–2025

Across 29 payments — averaging $270.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$7K
  • Johnson & Johnson$235
  • AstraZeneca$131
  • Pfizer$21
  • Otsuka America Pharmaceutical, Inc.$18
  • Amgen$17
  • plus $32 from 2 others

What the payments were for

  • Consulting fees$91012%
  • Speaking & faculty fees$5,46070%
  • Travel & lodging$89611%
  • Food & beverage$5757%

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,841 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.

See all internal medicine providers in Montana

Medicare billing

Part B allowed, 2024
$89,163
Medicare patients
651
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$172,383
EliquisApixaban145$126,310
JardianceEmpagliflozin88$103,368
TrulicityDulaglutide58$70,732
JanuviaSitagliptin Phosphate50$35,834
FarxigaDapagliflozin Propanediol15$25,389
Tresiba Flextouch U-200Insulin Degludec21$24,297
Tresiba Flextouch U-100Insulin Degludec22$18,930
XareltoRivaroxaban13$16,827
PremarinEstrogens, Conjugated39$13,883
Advair HfaFluticasone Propion/Salmeterol28$13,742
MounjaroTirzepatide12$12,633
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$12,547
Breo ElliptaFluticasone/Vilanterol30$11,124
Victoza 3-PakLiraglutide14$10,451

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$21$140,193184 claims
AstraZenecaFarxiga$131$25,38915 claims
Johnson & JohnsonXarelto$235$16,82713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.

Other internal medicine in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →